Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tragrisso

- PMLiVE

AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine

CHMP could reach a decision on opinion by 29 January

- PMLiVE

AZ/Oxford University COVID-19 vaccine wins emergency approval in India

In June 2020, AZ signed a licensing deal with the Serum Institute for the vaccine

- PMLiVE

First person in the UK given AstraZeneca/Oxford University COVID-19 vaccine

The vaccine can be stored at standard refrigerator temperatures

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

- PMLiVE

AstraZeneca to acquire Alexion for $39bn

Deal will bolster AZ's portfolio with rare disease assets

- PMLiVE

The Lancet confirms effectiveness of AZ/Oxford University’s COVID-19 vaccine

Final average efficacy analysis found to be 70.4%

- PMLiVE

AZ divests European rights for cholesterol med Crestor to Grünenthal

Grünenthal will pay up to $350m for the rights

- PMLiVE

AZ, Oxford University face more scrutiny over COVID-19 vaccine data

WHO’s immunisations director says ‘more than a press release’ is needed

- PMLiVE

AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%

Across two dosing regimens, vaccine has average efficacy of 70%

- PMLiVE

Chief investigator of Oxford Vaccine Group says data could be released before Christmas

AstraZeneca is developing a COVID-19 vaccine with Oxford University

- PMLiVE

AZ’s COVID-19 vaccine proves promising in elderly participants, new data shows

Immune responses were similar in younger and older adults

Roche Basel Switzerland

Roche’s flu pill Xofluza moves closer towards EU approval

CHMP recommends drug for approval in the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links